0 results for 'Novo Nordisk'
TV Legal Ads Proving Useful Radar for Next Big Mass Tort Categories
Tracking television legal ads that solicit plaintiffs for mass torts can give general counsel early warning of new trends and gauge the plaintiffs' bar's appetite in product litigation categories.Despite Cuts, Fenwick Sees Revenue Growth and Remains Bullish on Tech Business Bounceback
"Some uncertainty remains. But it will come back, and come back stronger," said firm chair Richard Dickson about the firm's scope of work. "We just don't know exactly when."Social Media Ads Inject New Angle in Ozempic Cases: 'It's Going to Be a Huge Focus'
The proliferation of advertising on social media for Ozempic and related drugs will be a key part of the lawsuits against Novo Nordisk and Eli Lilly.Don't Be Cranky and Don't Cause Delays: Judge Pushes for Efficiency in Ozempic MDL
"What I want is to avoid asking for continuances and asking for delay and asking for new dates. Just pick your poison and stick with it," Pratter told the approximately 70 people gathered in her courtroom Thursday.View more book results for the query "Novo Nordisk"
Yes, Deal Activity is Surging. But How Long Will It Last?
Kirkland & Ellis, Latham & Watkins, Skadden, Arps, Slate, Meagher & Flom and other law firms with large transactional practices may see the recent rush of deals as the sign they've been waiting for. The Global Lawyer suggests they may want to curb their enthusiasm.Deals Are Back. But Don't Get Too Excited
Firms with large transactional practices may see the recent rush of deals as the sign they've been waiting for. The Global Lawyer suggests they may want to curb their enthusiasm.Deals Are Back. But Don't Get Too Excited
Kirkland & Ellis, Latham & Watkins, Skadden, Arps, Slate, Meagher & Flom and other law firms with large transactional practices may see the recent rush of deals as the sign they've been waiting for. The Global Lawyer suggests they may want to curb their enthusiasm.Deal Watch: Wachtell, Paul Weiss and V&E Lead $26B Oil Merger as Deal Activity Soars
Energy and life sciences continue to lead the way in deal activity, but tech and other recently nascent sectors are showing signs of life.Judge Rejects Class Action Claim Filed Against Novo Nordisk, Eli Lilly and Sanofi-Aventis
"Plaintiffs have not sufficiently shown they failed to receive the benefit of the bargain as they have not alleged that they had 'a reasonable belief about the product induced by a misrepresentation'—and in fact they have asserted the opposite, that their ascertainable loss theory is not based on misrepresentation—or that they were misled into buying insulin that was worth less than was promised," Judge Brian R. Martinotti said.Download Now
Download Now
Download Now
Download Now